Summary of Significant Accounting Policies (Tables)
|
6 Months Ended |
Jun. 30, 2025 |
Summary of Significant Accounting Policies [Abstract] |
|
Schedule of Long-Lived Assets |
| |
Re-Tain® Assets as of June 30, 2025 | |
Land | |
$ | 448,201 | |
Buildings and improvements | |
| 12,725,789 | |
Laboratory and manufacturing equipment | |
| 9,769,049 | |
Construction in progress | |
| 2,316,951 | |
Total | |
| 25,259,990 | |
Accumulated depreciation | |
| (9,496,221 | ) |
Net book value | |
$ | 15,763,769 | |
|
Schedule of Assets or Liabilities Measured at Fair Value on a Nonrecurring Basis |
These fair market values are reflected in the following tables:
| |
As of June 30, 2025 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets: | |
| | |
| | |
| | |
| |
Cash and money market accounts | |
$ | 5,998,494 | | |
$ | — | | |
$ | — | | |
$ | 5,998,494 | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Bank debt | |
$ | — | | |
$ | 9,016,678 | | |
$ | — | | |
$ | 9,016,678 | |
| |
As of December 31, 2024 | |
| |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
Assets: | |
| | |
| | |
| | |
| |
Cash and money market accounts | |
$ | 3,758,232 | | |
$ | — | | |
$ | — | | |
$ | 3,758,232 | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Bank debt | |
$ | — | | |
$ | 9,465,500 | | |
$ | — | | |
$ | 9,465,500 | |
|
Schedule of Concentration of Risk |
Sales to significant customers that amounted
to 10% or more of total product sales are detailed in the following table:
| |
During
the Three-Month
Periods Ended June 30, | | |
During
the Six-Month
Periods Ended June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
Company A | |
| 52 | % | |
| 44 | % | |
| 47 | % | |
| 45 | % |
Company B | |
| 29 | % | |
| 33 | % | |
| 28 | % | |
| 34 | % |
Total | |
| 81 | % | |
| 77 | % | |
| 75 | % | |
| 79 | % |
Trade accounts receivable due from significant
customers that amounted to 10% or more of our total trade accounts receivable are detailed in the following table:
| |
| | |
| |
Company A | |
| 44 | % | |
| 57 | % |
Company B | |
| 35 | % | |
| 21 | % |
Total | |
| 79 | % | |
| 78 | % |
|
Schedule of Net Income (Loss) Per Common Share |
Outstanding stock options that were not included in this calculation
because the effect would be anti-dilutive amounted to 618,000 during both the three-month period and the six-month period ended June 30,
2024.
| |
During
the Three-Month
Periods Ended June 30, | | |
During
the Six-Month
Periods Ended June 30, | |
| |
2025 | | |
2024 | | |
2025 | | |
2024 | |
Net income (loss) attributable to stockholders | |
$ | 501,880 | | |
$ | (1,531,626 | ) | |
| 1,948,863 | | |
$ | (1,969,494 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding - Basic | |
| 9,031,282 | | |
| 7,810,037 | | |
| 9,006,082 | | |
| 7,780,450 | |
Dilutive impact of share-based compensation awards | |
| — | | |
| — | | |
| — | | |
| — | |
Weighted average common shares outstanding - Diluted | |
| 9,031,282 | | |
| 7,810,037 | | |
| 9,006,082 | | |
| 7,780,450 | |
| |
| | | |
| | | |
| | | |
| | |
Net income (loss) per share: | |
| | | |
| | | |
| | | |
| | |
Basic | |
$ | 0.06 | | |
$ | (0.20 | ) | |
$ | 0.22 | | |
$ | (0.25 | ) |
Diluted | |
$ | 0.06 | | |
$ | (0.20 | ) | |
$ | 0.22 | | |
$ | (0.25 | ) |
|